Citations

Showing 10 of 108104 citations.

Reply to “How should decision aids be developed, and which patient outcomes should be assessed?”
Kim, Simon P. , Tilburt, Jon C.

Mayo Clinic

Cancer | May 4, 2022 | Volume: 128 | Issue: 15 | Pages: 2990-2990

10.1002/cncr.34246 | PMID 35507239 Get It

Deep Learning for Radiographic Measurement of Femoral Component Subsidence Following Total Hip Arthroplasty
Rouzrokh, Pouria , Wyles, Cody C. , Kurian, Shyam J. , Ramazanian, Taghi , Cai, Jason , Huang, Qiao , Zhang, Kuan , Kremers, Hilal Maradit , Erickson, Bradley J. , Maradit Kremers, Hilal , Erickson, Bradley J , Wyles, Cody C , Rouzrokh, Pouria , Taunton, Michael J.

Mayo Clinic

Radiology: Artificial Intelligence | May 4, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1148/ryai.210206 | PMID 35652119 Get It

New bone formation over dehiscent semicircular canal with cartilage cap
Bhatt, Alok A. , Zapala, David A., Pooley, Robert A. , Lundy, Larry, Vibhute, Prasanna , Lundy, Larry B, Bhatt, Alok A , Gupta, Vivek

Mayo Clinic

The Neuroradiology Journal | May 4, 2022 | Volume: 35 | Issue: 6 | Pages: 724-726

10.1177/19714009221096820 | PMID 35506568 Get It

Purpose Cartilage cap resurfacing is a method to seal a superior semicircular canal dehiscence. The purpose of this study was to evaluate the detection of new bone formation after surgical placement of a cartilage cap over a dehiscent semicircular canal. Methods In this retrospective review, two neuroradiologists blinded to each other’s interpretation reviewed the temporal bones of 20 patients, five of which had a pre-operative computed tomography (CT) exam which was interpreted as unilateral superior semicircular canal dehiscence and with new bone formation following repair on follow-up CT. There were also 15 control subjects. Each neuroradiologist was blinded to history, including post-operative changes, and asked to determine if there was a dehiscence or no dehiscence. Results Out of the 15 controls, there was 100% inter-observer agreement. On the five post-operative patients, there was agreement in 4/5 that there was no dehiscence post-operatively and 1/5 agreement of dehiscence post-operatively, but ectopic bone adjacent to the dehiscence. Conclusion Our results indicate that new bone formation can be seen at the site of cartilage cap placement over the dehiscence and be interpreted as bony closure of the dehiscence.
Multimodality imaging evaluation of incidentally discovered intracardiac mass
Saef, Josh , Jellis, Christine , Unai, Shinya , Tan, Carmela D. , Dresing, Thomas , Ayoub, Chadi , Ayoub, Chadi

Mayo Clinic

Echocardiography | May 4, 2022 | Volume: 39 | Issue: 6 | Pages: 837-840

10.1111/echo.15354 | PMID 35505607 Get It

AbstractIncidentally discovered intracardiac masses often represent diagnostic dilemmas. No guideline‐directed algorithm exists for evaluation and management in these cases. Understanding the utility and limitations of different imaging modalities expedites evaluation of differential diagnoses and management, particularly when there are discordant imaging findings. This case further demonstrates that benign cardiac tumors may grow rapidly, and that new and rapid emergence of an intracardiac mass does not necessarily correlate with a diagnosis of thrombus or malignancy. It also highlights the importance of a broad differential diagnosis and a systematic management approach in patients with intracardiac masses.
Effect of Antihypertensives by Class on Cerebral Small Vessel Disease: A Post Hoc Analysis of SPRINT-MIND
Goldstein, Eric , Wolcott, Zoe , Garg, Gauri, Navarro, Kayla , Delic, Alen, Yaghi, Shadi , Sederholm, Benson , Prabhakaran, Shyam , Wong, Ka-Ho , McLean, Kaitlin, Goldstein, Eric D , de Havenon, Adam H , Yaghi, Shadi , Prabhakaran, Shyam , Wolcott, Zoe , Garg, Gauri, Navarro, Kayla , Delic, Alen, Sederholm, Benson , Wong, Ka-Ho , McLean, Kaitlin

Mayo Clinic

Stroke | May 4, 2022 | Volume: 53 | Issue: 8 | Pages: 2435-2440

10.1161/strokeaha.121.037997 | PMID 35506388 Get It

Background: Treatment of uncontrolled arterial hypertension reduces the risk of cerebral small vessel disease (CSVD) progression, although it is unclear whether this reduction occurs due to blood pressure control or class-specific pleiotropic effects, such as improved beat-to-beat arterial pressure variability with calcium channel blockers. The goal of this study was to investigate the influence of antihypertensive medication class, particularly with calcium channel blocker, on accumulation of white matter hyperintensities (WMH), a radiographic marker of CSVD, within a cohort with well-controlled hypertension. Methods: We completed an observational cohort analysis of the SPRINT-MIND trial (Systolic Blood Pressure Trial Memory and Cognition in Decreased Hypertension), a large randomized controlled trial of participants who completed a baseline and 4-year follow-up brain magnetic resonance image with volumetric WMH data. Antihypertensive medication data were recorded at follow-up visits between the magnetic resonance images. A percentage of follow-up time participants were prescribed each of the 11 classes of antihypertensive was then derived. Progression of CSVD was calculated as the difference in WMH volume between 2 scans and, to address skew, dichotomized into a top tertile of the distribution compared with the remaining. Results: Among 448 individuals, vascular risk profiles were similar across WMH progression subgroups except age (70.1±7.9 versus 65.7±7.3 years; P <0.001) and systolic blood pressure (128.3±11.0 versus 126.2±9.4 mm Hg; P =0.039). Seventy-two (48.3%) of the top tertile cohort and 177 (59.2%) of the remaining cohort were in the intensive blood pressure arm. Those within the top tertile of progression had a mean WMH progression of 4.7±4.3 mL compared with 0.13±1.0 mL ( P <0.001). Use of angiotensin-converting enzyme inhibitors (odds ratio, 0.36 [95% CI, 0.16–0.79]; P =0.011) and dihydropyridine calcium channel blockers (odds ratio, 0.39 [95% CI, 0.19–0.80]; P =0.011) was associated with less WMH progression, although dihydropyridine calcium channel blockers lost significance when WMH was treated as a continuous variable. Conclusions: Among participants of SPRINT-MIND trial, angiotensin-converting enzyme inhibitor was most consistently associated with less WMH progression independent of blood pressure control and age.
Isolation of Pseudomonas aeruginosa after nontuberculous mycobacteria
Henkle, Emily , Aksamit, Timothy R. , Winthrop, Kevin , Brunton, Amanda E.

Mayo Clinic

The International Journal of Tuberculosis and Lung Disease | May 4, 2022 | Volume: 26 | Issue: 5 | Pages: 460-462

10.5588/ijtld.21.0572 | PMID 35505473 Get It

BETA: a comprehensive benchmark for computational drug–target prediction
Zong, Nansu , Li, Ning , Ngo, Victoria , Yu, Yue , Chowdhury, Shaika , Jiang, Chao , Weinshilboum, Richard M. , Jiang, Guoqian , Chowdhury, Shaika , Weinshilboum, Richard, Wen, Andrew , Huang, Ming , Fu, Sunyang , Weinshilboum, Richard M. , Hunter, Lawrence , Liu, Hongfang

Mayo Clinic

Briefings in Bioinformatics | May 4, 2022 | Volume: 23 | Issue: 4 | Pages: No page available

10.1093/bib/bbac199 | PMID 35649342 Get It

Abstract Internal validation is the most popular evaluation strategy used for drug–target predictive models. The simple random shuffling in the cross-validation, however, is not always ideal to handle large, diverse and copious datasets as it could potentially introduce bias. Hence, these predictive models cannot be comprehensively evaluated to provide insight into their general performance on a variety of use-cases (e.g. permutations of different levels of connectiveness and categories in drug and target space, as well as validations based on different data sources). In this work, we introduce a benchmark, BETA, that aims to address this gap by (i) providing an extensive multipartite network consisting of 0.97 million biomedical concepts and 8.5 million associations, in addition to 62 million drug–drug and protein–protein similarities and (ii) presenting evaluation strategies that reflect seven cases (i.e. general, screening with different connectivity, target and drug screening based on categories, searching for specific drugs and targets and drug repurposing for specific diseases), a total of seven Tests (consisting of 344 Tasks in total) across multiple sampling and validation strategies. Six state-of-the-art methods covering two broad input data types (chemical structure- and gene sequence-based and network-based) were tested across all the developed Tasks. The best-worst performing cases have been analyzed to demonstrate the ability of the proposed benchmark to identify limitations of the tested methods for running over the benchmark tasks. The results highlight BETA as a benchmark in the selection of computational strategies for drug repurposing and target discovery.
Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer
Barfield, Richard , Huyghe, Jeroen R. , Lemire, Mathieu, Dong, Xinyuan, Su, Yu-Ru, Buchanan, Daniel D. , Figueiredo, Jane C. , Gallinger, Steven, Giannakis, Marios, Gsur, Andrea , Gunter, Marc J. , Harrison, Tabitha A. , Hopper, John L., Li, Christopher I., Newcomb, Polly A., Pai, Rish K. , Phipps, Amanda I., Qu, Conghui, Steinfelder, Robert S., Win, Aung Ko , Zaidi, Syed H., Peters, Ulrike , Brezina, Stefanie , Buchanan, Daniel D , Figueiredo, Jane C , Gsur, Andrea , Gunter, Marc J , Hampel, Heather , Harrison, Tabitha A , Hudson, Thomas J , Moreno, Victor , Pai, R K , Pharoah, Paul D P , Sun, Wei , Win, Aung K , Campbell, Peter T , Peters, Ulrike , Hsu, Li , Barfield, Richard , Huyghe, Jeroen R , Lemire, Mathieu, Dong, Xinyuan, Su, Yu-Ru, Gallinger, Steven, Giannakis, Marios, Hopper, John L., Li, Christopher I., Newcomb, Polly A., Phipps, Amanda I., Qu, Conghui, Steinfelder, Robert S., Zaidi, Syed H.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 4, 2022 | Volume: 31 | Issue: 5 | Pages: 1068-1076

10.1158/1055-9965.epi-21-0724 | PMID 35247911 Get It

Abstract Background: Colorectal cancer has a strong epigenetic component that is accompanied by frequent DNA methylation (DNAm) alterations in addition to heritable genetic risk. It is of interest to understand the interrelationship of germline genetics, DNAm, and colorectal cancer risk. Methods: We performed a genome-wide methylation quantitative trait locus (meQTL) analysis in 1,355 people, assessing the pairwise associations between genetic variants and lymphocytes methylation data. In addition, we used penalized regression with cis-genetic variants ± 1 Mb of methylation to identify genome-wide heritable DNAm. We evaluated the association of genetically predicted methylation with colorectal cancer risk based on genome-wide association studies (GWAS) of over 125,000 cases and controls using the multivariate sMiST as well as univariately via examination of marginal association with colorectal cancer risk. Results: Of the 142 known colorectal cancer GWAS loci, 47 were identified as meQTLs. We identified four novel colorectal cancer–associated loci (NID2, ATXN10, KLHDC10, and CEP41) that reside over 1 Mb outside of known colorectal cancer loci and 10 secondary signals within 1 Mb of known loci. Conclusions: Leveraging information of DNAm regulation into genetic association of colorectal cancer risk reveals novel pathways in colorectal cancer tumorigenesis. Our summary statistics-based framework sMiST provides a powerful approach by combining information from the effect through methylation and residual direct effects of the meQTLs on disease risk. Further validation and functional follow-up of these novel pathways are needed. Impact: Using genotype, DNAm, and GWAS, we identified four new colorectal cancer risk loci. We studied the landscape of genetic regulation of DNAm via single-SNP and multi-SNP meQTL analyses.
B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS
Wang, Sophia , Vajdic, Claire M. , Linet, Martha S. , Slager, Susan L. , Nieters, Alexandra, Casabonne, Delphine , Cerhan, James R. , Cozen, Wendy , Brown, Elizabeth E. , Bracci, Paige M. , Turner, Jennifer , Hjalgrim, Henrik , Bhatti, Parveen , Flowers, Christopher R. , Paltiel, Ora , Holly, Elizabeth A., Weisenburger, Dennis D. , Cocco, Pierluigi , Breen, Elizabeth C. , Lan, Qing , Roos, Anneclaire J. De , Smith, Martyn T. , Kricker, Anne , Zheng, Tongzhang, Skibola, Christine F., Clavel, Jacqueline , Monnereau, Alain, Rothman, Nathaniel , Benavente, Yolanda , Hartge, Patricia, Smedby, Karin E. , Monnereau, Alain , Wang, Sophia S , Cerhan, James R , Cozen, Wendy , Martínez-Maza, Otoniel , Turner, Jennifer , Hjalgrim, Henrik , Bhatti, Parveen , Birmann, Brenda M , Kane, Eleanor , Weisenburger, Dennis D , Maynadié, Marc , Cocco, Pierluigi , Breen, Elizabeth Crabb , Lan, Qing , Brooks-Wilson, Angela R , Roman, Eve , Boffetta, Paolo , Kricker, Anne , Clavel, Jacqueline , Vajdic, Claire M , De Roos, Anneclaire J , Slager, Susan L , Voutsinas, Jenna M. , Alarcón, Graciela S. , Martı́nez-Maza, Otoniel , Zhang, Yawei , Birmann, Brenda M. , Kane, Eleanor , Foretová, Lenka , Brooks‐Wilson, Angela , Roman, Eve , Chanock, Stephen Jacob , Rothman, Nathaniel

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 4, 2022 | Volume: 31 | Issue: 5 | Pages: 1103-1110

10.1158/1055-9965.epi-21-0875 | PMID 35244686 Get It

Abstract Background: A previous International Lymphoma Epidemiology (InterLymph) Consortium evaluation of joint associations between five immune gene variants and autoimmune conditions reported interactions between B-cell response-mediated autoimmune conditions and the rs1800629 genotype on risk of B-cell non–Hodgkin lymphoma (NHL) subtypes. Here, we extend that evaluation using NHL subtype-specific polygenic risk scores (PRS) constructed from loci identified in genome-wide association studies of three common B-cell NHL subtypes. Methods: In a pooled analysis of NHL cases and controls of Caucasian descent from 14 participating InterLymph studies, we evaluated joint associations between B-cell–mediated autoimmune conditions and tertile (T) of PRS for risk of diffuse large B-cell lymphoma (DLBCL; n = 1,914), follicular lymphoma (n = 1,733), and marginal zone lymphoma (MZL; n = 407), using unconditional logistic regression. Results: We demonstrated a positive association of DLBCL PRS with DLBCL risk [T2 vs. T1: OR = 1.24; 95% confidence interval (CI), 1.08–1.43; T3 vs. T1: OR = 1.81; 95% CI, 1.59–2.07; P-trend (Ptrend) &lt; 0.0001]. DLBCL risk also increased with increasing PRS tertile among those with an autoimmune condition, being highest for those with a B-cell–mediated autoimmune condition and a T3 PRS [OR = 6.46 vs. no autoimmune condition and a T1 PRS, Ptrend &lt; 0.0001, P-interaction (Pinteraction) = 0.49]. Follicular lymphoma and MZL risk demonstrated no evidence of joint associations or significant Pinteraction. Conclusions: Our results suggest that PRS constructed from currently known subtype-specific loci may not necessarily capture biological pathways shared with autoimmune conditions. Impact: Targeted genetic (PRS) screening among population subsets with autoimmune conditions may offer opportunities for identifying those at highest risk for (and early detection from) DLBCL.